Introduction
Despite many improvements in the efficacy of anticancer agents, the resistance of tumor cells to cytostatic drugs remains the major cause of treatment failure in patients with disseminated malignant diseases. As a paradigm, multiagent chemotherapy induces complete hematological remission in most patients with acute myeloid leukemia (AML), but the majority of such patients still experience relapse and will finally succumb to the disease. 1 On the cellular level, such leukemic cells initiating relapse must combine in one cell the resistance to cytostatic drugs with the capacity for clonal outgrowth. [2] [3] [4] Applying the Hoechst 33342 staining technique to isolate stem cells with side population (SP) properties, 5 we described such a leukemic progenitor cell with intrinsic drug efflux capacity some years ago. 6 Consecutively, we and others have detected malignant SP cells exhibiting progenitor cell properties both in vitro and in vivo in numerous other types of cancer. 7 As for the mechanism of dye and drug exclusion, we first discovered the overexpression of the ATP-binding cassette transporter A3 (ABCA3) in leukemic SP cells in an in-vivo leukemia model. Those data were confirmed in series of malignant SP cells from both patients with neuroblastoma and AML. [7] [8] [9] Here we demonstrate that ABCA3 was expressed in virtually all cases of AML from a series of 119 pediatric and adult patients, and that high levels of expression are associated with a significantly impaired prognosis. We discovered that expression of ABCA3 induces a phenotype of broad multidrug resistance (MDR), mediated by subcellular drug sequestration to lysosomes and finally gathered evidence of ABCA3 expression in all major types of malignant lymphohematopoietic disease.
Patients, materials and methods

Patients
For the AML cohort of 119 patients, the bone marrow (n ¼ 112) and peripheral blood (n ¼ 7) specimens analyzed in this study represented archival diagnostic material collected from children treated within the German multicenter BFM98 protocol, and adults treated according to the German HD98A and B protocol at the University Hospital in Goettingen, Germany. The study was submitted to the Ethics Committee of the University of Goettingen, and no objections were raised. The clinical characteristics of the AML study population are reported in Supplemental Table 1 . As control samples, adult human bone marrow progenitor cells were isolated from routine diagnostic posterior iliac crest aspirates of individuals without marrow disease involvement, again following internal review board (IRB) approval. The tissue array of aggressive lymphomas was collected from patients participating in the German multicenter studies NHLB1, NHLB2 and the Mabthera International Trial of the German high-grade lymphoma study group. Informed consent to the scientific evaluation of the tissue samples was obtained from the patients on study inclusion, and permission for this analysis was obtained from the IRB of the Deutsche Studiengruppe Hochmaligne Non-Hodgkin-Lymphome study group.
Reagents, cells, plasmids and antibodies
The stable ABCA3-eGFP and green fluorescent protein (GFP) transfectants HEK293-ABCA3/eGFP and HEK293-eGFP were obtained from the embryonic kidney cell line HEK293 as described previously and were routinely propagated in Dulbecco's modified Eagle's medium supplemented with 300 mg/ml G418. For cytotoxicity assays, the transfected cell lines were propagated without G418 for four passages, without losing transgene expression as evaluated by fluorescence microscopy. The pEGFP-N1-ABCA3 wild-type (wt) and pEGFP-N1-ABCA3 N568D mutant plasmids were described previously. 10 The monoclonal mouse antibody to early endosomal antigen 1 (EEA1) was obtained commercially (Transduction Laboratories), the antibodies to lysosomal-associated membrane protein 1 (LAMP1, code H4A3) and LAMP2 (code H4B4) were from the Developmental Studies Hybridoma Bank (Iowa City, IA, USA). Human MPR46 was detected using the monoclonal antibody (code 10C6), and human ABCA3 with a polyclonal rabbit antihuman ABCA3 antibody. 11 The myeloid leukemia cell line HL60 (DSMZ, Braunschweig, Germany) was propagated in RPMI 1640 supplemented with 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, GlutaMAX I (Gibco-BRL, Karlsruhe, Germany), penicillin/streptomycin (Sigma, Steinheim, Germany and Biochrom, Berlin, Germany) and 10% heat-inactivated fetal calf serum (Gibco-BRL). The T-cell lymphoma/leukemia cell lines Jurkat and HUT78 (DSMZ) and the variant PM1 of HUT78, as well as the natural killer (NK) cell line YT (DSMZ) were also propagated in RPMI 1640 supplemented as above. The NK cell line NK92 (kindly provided by T Tonn, Frankfurt, Germany) was cultured in X-vivo medium (BioWhittaker, Taufkirchen, Germany), containing 5% human AB plasma supplemented with 100 U/ml interleukin -2 (R&D Systems, Minneapolis, MN, USA). The aggressive B-cell lymphoma/leukemia cell lines Balm3, Raji, Karpas 422, Ramos, SuDHL4 (DSMZ) as well as the Hodgkin's cell lines HDLM2, L1236 and L428 (DSMZ) and the mantle cell lymphoma cell lines Granta 519, Mino and Sp53 (ATCC, Manassas, VA, USA) were maintained in RPMI 1640 supplemented as above.
Cell separation and flow cytometry
Mononuclear cells (MNC) were separated from whole blood or bone marrow aspirates using density centrifugation with Ficoll (Pharmacia, Uppsala, Sweden). A FACScan cytometer (Becton Dickinson, Heidelberg, Germany) was used for the flow cytometric analysis resulting from the excitation of eGFP (fluorescein isothiocyanate) and daunorubicin (DNR) at 488 nm. Data were analyzed with CellQuest (Becton Dickinson) or WinMDI (Trotter, 1999) software. Cell sorting by flow cytometry was performed on the FACSVantage SE. Purity was determined with FACS, and only samples exceeding 90% marker expression after positive selection were used in further experiments.
RNA preparation and PCR
Total RNA was isolated from MNC or cell line preparations with the RNeasy kit (Qiagen, Hamburg, Germany) according to the manufacturer's instructions, suspended in RNAase-free-distilled water, and quantified using a spectrophotometer. Superscript II reverse polymerase (Invitrogen, Karlsruhe, Germany) was used for cDNA synthesis, and quantitative reverse transcriptase polymerase chain reactions (qRT-PCR) of hABCA3 and b-actin transcripts were performed in duplicates on a TaqMan cycling machine (ABI Prism 7900HT Sequence Detection System, Applied Biosystems, Darmstadt, Germany). The SYBR green kit (Qiagen) was used according to the manufacturer's protocols, with 40 cycles of denaturation (15 s at 95 1C), annealing (30 s at 58 1C) and elongation (60 s at 72 1C) followed by a melting curve analysis. Subsequently, the threshold PCR cycle number (C T ) was obtained when the increase in the fluorescence signal of the PCR product indicated exponential amplification. This value was then normalized to the threshold PCR cycle number obtained for b-actin mRNA from a parallel sample. The hABCA3 primer (us 5 0 -TTCTTCACCTACATCCCCTAC-3 0 ; ds 5 0 -CCTTTCG CCTCAAATTTCCC-3 0 ) yielded an amplicon of 139 bp, the b-actin primer (us 5 0 -CACACTGTGCCCATCTACGA-3 0 ; ds 5 0 -TGA GGATCTTCATGAGCTAGTCAG-3 0 ) and amplicon of 99 bp. Transcripts of mRNA from the cell line HL60, which displayed weak expression of hABCA3 both on the RNA and protein levels, were run in parallel with all reactions, and the values of ABCA3 levels were reported using HL60 with the expression level of 1 as standard.
Microscopy
For the routine detection of ABCA3 on sorted cell populations, we performed indirect immunocytology following cytocentrifugation for 10 min at 800 g and fixation with 4% paraformaldehyde (PFA)/phosphate-buffered saline (PBS). The primary antibody to ABCA3, a polyclonal rabbit serum, was diluted 1:200 in PBS and incubated overnight. Cells were fixed in 4% PFA/PBS, followed by blocking of endogenous peroxidase and visualized using the horseradish peroxidase reaction with the Envision system according to the manufacturer's instructions (Vector, Peterborough, UK). Likewise, deparaffination, fixation with 4% PFA/PBS, antigen retrieval in citrate-based buffer, and antibody stains as above were performed on paraffin tissue sections arranged in multi-tissue arrays according to standard protocols. ABCA3 cytoplasmic staining levels were quantified by panel agreement of three independent reviewers as negative
Pappenheim's panoptic and myeloid peroxidase stains of hematopoietic cells, and hematoxylin/eosin stains of tissue sections were performed according to the standard protocols. In order to carry out fluorescence colocalization work, HEK293-ABCA3/eGFP cells were grown on 24-well cover slips to 50% confluency prior to experimentation. At room temperature, cells were fixed using 3.7% PFA for 20 min, with the subsequent quenching of any unspecific binding using 50 mM NH 4 Cl for 15 min and permeabilization with 0.05% Triton X-100 in PBS for 15 min. Primary antibodies to EEA1, LAMP1 and MPR46 for the colocalization study were diluted 1:100 in PBS for 1 h. After washing twice with PBS and incubating with 10% goat serum, the primary antibodies were visualized using goat secondary antibodies at a dilution of 1:500 in PBS coupled to Cy3 (Dianova, Hamburg, Germany). All samples were mounted in Fluoromount (DAKO, Hamburg, Germany) and analyzed with the TCS-2 AOBS confocal laser scanning microscope (Leica) with a Â 63 inversion oil objective (Leica). The data were exported as TIFF files and arranged using Adobe PhotoShop without further modification of the primary image. All images from confocal sections were obtained under identical microscopic settings. For the supravital lysosome staining and tracking of DNR (Sigma), cells were grown on 24-well cover slips to 50% confluency prior to experimentation (in the case of adherent cells) or to a density of 2 Â 10 6 cells per ml growth medium (in the case of suspension cultures). Lysotracker Red (50-100 nM, Molecular Probes, Karlsruhe, Germany) was incubated with the cells at 37 1C for 1 h. In order to visualize subcellular DNR, cells were incubated with 2.5 mM DNR at 37 1C for 2 h, followed by washing with PBS. The viable cells were analyzed for subcellular DNR and eGFP fluorescence directly after washing, and after a 24 h period of washout in fresh medium in cell culture. Confocal sections were obtained as described above.
Immunoelectron microscopy was performed according to the Tokuyasu method. Wild-type HEK293, transfectants overexpressing ABCA3, and MNC of AML samples were fixed with 2% PFA and 0.1% glutaraldehyde in 0.1 M sodium phosphate (pH 7.4) at room temperature for 30 min, before the cells were postfixed with 4% PFA and 0.1% glutaraldehyde on ice for 2 h. After being washed twice with PBSF0.02% glycine, the cells were embedded in 10% gelatin, cooled on ice and cut into small blocks. The blocks were infused with 2.3 M sucrose overnight and stored in liquid nitrogen. Ultrathin cryosections were cut from the frozen samples and labeled with primary antibodies detected with protein A conjugated to gold (protein A gold, PAG). In the case of monoclonal antibodies, a polyclonal rabbit anti-mouse bridging antibody (Sigma) was used prior to detection with PAG. Sections were contrasted with uranyl acetate methyl cellulose on ice for 10 min, embedded in the same solution and examined with a Phillips CM120 electron microscope. In preparation of whole cell imaging, cells were fixed in 2% glutaraldehyde in 0.1 M PBS, pH 7.4, for 2 h, postfixed in 1% OsO 4 for 1 h, dehydrated in ethanol and then embedded in Epon.
Transfer of plasmid DNA and siRNA
For plasmid transfer, 1 Â 10 6 cells in 150 ml OptiMEM (Gibco-BRL) were mixed in a prechilled cuvette (Biozym, Hess. Oldendorf, Germany) with 10 mg of either pmax-GFP, pEGFP-N1-ABCA3 wt or pEGFP-N1-ABCA3 N568D, pulsed in an EasyjecT (Equi Bio, Middlesex, UK) electroporator (300 V, 1050 mF, 99 O, t: 104 ms) and incubated for 3 h in 400 ml OptiMEM before further expansion with 1.5 ml of complete growth medium overnight. For the transfer of specific, doublestranded, predesigned siRNA against ABCA3 (Qiagen; sense 5 0 -CGGAGAAAUUACAUGUGGA-dTdT-3 0 ; antisense sequence, 5 0 -UCCACAUGUAAUUUCUCCG-dTdG-3 0 ; coding region starts at position 1035 relative to the start codon) in suspension cell cultures, 50 nM siRNA against hABCA3 were electroporated with a program optimized for RNA transfer (300 V, 150 mF, 1540 O, t: 231 ms). Transfer efficiency, as measured with the transfer of Alexa488 tagged scrambled siRNA (Qiagen; sense 5 0 -UUCUCCGAACGUGUCACG-UdT-3 0 ; antisense 5 0 -ACGUGA CACGUUCGGAGA-AdT-3 0 ), routinely exceeded 80%. In the case of adherent cells, chemical transfection (Hyperfect, Qiagen) was used yielding similar degrees of efficiency according to the manufacturer's recommendations. Using siRNA knockdown, the nadir of ABCA3 mRNA and protein expression was documented as occurring 72 h after electroporation, as tested by qRT-PCR and FACS.
Viability and clonogenicity assays, daunorubicin measurements
For viability testing by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test, cells were seeded in triplicates on 96-well culture plates at a density of 1 Â 10 5 cells per well and were treated with the indicated concentrations of DNR (Sigma), mitoxantrone (Wyeth, Mü nster, Germany), etoposide (Hexal, Holzkirchen, Germany), vincristine (Cell Pharm, Bad Vilbel, Germany), cytosine arabinoside (Ara-C, Cell Pharm) and gemtuzumab ozogamicin (GO, Wyeth) for 3 h each, Figure 1 Expression of ATP-binding cassette transporter A3 (ABCA3) in acute myeloid leukemia (AML) blast cellsABCA3 expression was detected on the protein and mRNA levels in primary AML samples. Western blot analysis (a) of seven representative cases with a polyclonal antibody detecting ABCA3 at a molecular size of 188 kDa revealed marked inter-individual heterogeneity. In the myeloid cell line HL60, ABCA3 protein was detectable at only low levels, compared to strong expression after transfection with an ABCA3-expression vector. Immunocytology against ABCA3 further revealed notable heterogeneity within the blast cell population as a consistent finding in the clinical samples, with a representative example shown in (b), scale bar 2 mm. mRNA levels, measured by qRT-PCR normalized to b-actin housekeeping gene controls and represented on a logarithmic scale, are shown in a box-whisker plot (c) for clinical samples from the 109 AML patients, again documenting remarkable interindividual differences in ABCA3 expression. Analyzed in parallel with the AML samples, ABCA3 was not detectable in 7 of 11, or very low levels falling outside the scale of this plot in 4 of 11 bone marrow samples from normal volunteers (#).
washed and then incubated for a period of 24 h, except vincristine (48 h) and Ara-C (42 h). After 24 h at 37 1C, the culture volume of 100 ml was supplemented with MTT in PBS to achieve a final concentration of 0.5 mg/ml. After 4 h incubation, suspension cells were spun, the supernatant discarded and the pellet resuspended in 30% (v/v) dimethyl sulfoxide, 5% (v/v) formic acid and 1% (w/v) Triton-X100 (all from Sigma) dissolved in isopropanol. The light absorbance from formazan was measured at 540 nm on a Tecan SLT photometer (Tecan SLT Spectra). We expressed the effect on viability as the ratio of values from treated versus untreated samples, that is, specific viability is the ratio of absorbance with drug to absorbance of untreated control. IC 50 was defined as the concentration of drug causing a 50% inhibition of cell growth as compared with untreated control. To analyze clonogenicity of HEK293 wt and transfectants, cells were seeded on a 10 cm diameter dish and cultured to 20% confluency 24 h preceding drug exposure for 3 h as indicated. After drug removal by three rounds of washing, cells were propagated in culture medium for the time points indicated. Prior to macroscopic counting of cell clones, the culture dishes were fixed with 3.7% PFA/PBS for 30 min, washed and stained with hematoxylin for 5 min. All experiments were done in triplicate, with representative experiments for at least three independent assays being portrayed in the result section. In preparation of ionizing (g-radiation) and nonionizing (UVC light) irradiation, 1 Â 10 5 cells per well were plated either in 96-well plates (MTT assay) or 500 cells on a 10 cm diameter dish (clonogenicity assay) 24 h prior to irradiation. The doses of UVC radiation were 0, 10, 20, 30 or 40 J/m 2 , and those for g-radiation were 0, 2.5, 5, 7.5, 10 and 30 Gy, as indicated. Viability was assayed by MTT 48 h, clonogenicity 10 days after irradiation as described.
For DNR measurements, HEK293 and HEK293-ABCA3 cells were exposed to DNR for 1 h at the concentrations indicated. Following three washes with PBS, nuclei were isolated using the Nuclei EZ Prep Isolation Kit (Sigma) according to the manufacturer's recommendations. Briefly, cells were harvested in prechilled PBS after trypsination, and an aliquot of the cells was used to determine total cellular DNR retention. Thereafter, the cells were lysed for 5 min at 4 1C in lysis buffer, before the nuclei were collected by centrifugation at 500 g for 5 min. The pooled supernatant was collected as the organelle/cytosol pool. The nuclei were resuspended in PBS and the nuclear DNR fluorescence was analyzed at 560 nm after excitation at 488 nm on the flow cytometer. For subcellular fractionation, HEK293 and HEK293-ABCA3 cells were incubated for 3 h with 2.5 mM DNR. Subsequently, after washing with ice-cold PBS, cells were harvested from three 15 cm dishes from each cell line, homogenized and subcellular fractionation of the postnuclear supernatant (PNS) performed as detailed. Western blot and quantification of western blot results with ImageJ quantification program (rsb.info.nih.gov/ij/) were performed according to standard protocols.
Subcellular fractionation
After washing with ice-cold PBS, cells were harvested from three 15 cm dishes from each cell line, in 0.25 M sucrose buffered with 3 mM imidazole/HCl, pH 7.3, 1 mM EDTA and a 1:500 dilution of a protease inhibitor cocktail (Sigma) using five strokes of a G27 syringe. The PNS was prepared (5 min/500 g/4 1C) and 6 ml of this protein normalized PNS was adjusted to a final concentration of 20% Percoll solution (12 ml) in 0.25 M 
000 g without brakes in a vertical tube rotor Vti 65.1 (Beckmann Instruments, Krefeld, Germany). After removal of percoll, the supernatant and membranes were prepared by centrifuging each of the 23 fractions for 1 h at 100 000 g. Membranes were resuspended in 0.5% Triton X-100/PBS and used for further analysis, such as western blotting, determination of enzymatic activity and protein concentrations. DNR was measured within samples on Tecan Ultra Microplate Reader (TECAN, Mainz, Germany). The enzymatic activity of b-hexosaminidase, b-glucuronnidase and a-mannosidase was measured using either 10 mM p-nitrophenyl-2-acetamido-2-deoxy-b-D-glucopyranoside, 20 mM p-nitrophenyl-b-D-glucuronide or 10 mM p-nitrophenyl-a-D-mannopyranoside (all Sigma) as substrate, which was prepared at 10 mM in 0.1 M sodium citrate (pH 4.6). Usually 5-10 ml of the sample was mixed at 4 1C with 100 ml of the substrate, followed by 0.5-4 h of incubation at 37 1C. The reaction was stopped by adding 0.5 ml of 0.4 M glycine/NaOH (pH 10.4) and the specific activity was calculated after measuring the absorbance at 405 nm. 
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Figure 2 ATP-binding cassette transporter A3 (ABCA3) expression levels and chemotherapy treatment outcome in patients with acute myeloid leukemia (AML). Kaplan-Meier product limit estimates of progression-free survival (PFS, a), overall survival (OS, b) for patients (n ¼ 87) with newly diagnosed AML treated by pediatric multicenter and adult protocols, without stem cell transplant recipients. Low levels of ABCA3 expression (gray line) compared to high ABCA3 levels (black line) were significantly associated with both improved progression-free (P ¼ 0.0069) and OS (P ¼ 0.013) by log-rank test.
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Statistical evaluations
To carry out survival analysis on the patient data in the AML cohort, Kaplan-Meier analysis was employed, analyzing differences in survival from the time of diagnosis through progression (progression-free survival, PFS) or death of any cause (overall survival, OS). Multivariate analysis of confounding variables, that is, risk group according to karyotype (high-, intermediate-and low-risk according to Grimwade 12 was tested by Cox regression using Statistica 7.1 software (StatSoft) or R (R-Project). The threshold level of 0.5 arbitrary units in the qRT-PCR to separate low and high levels of expression of ABCA3 in a given sample was based on biological considerations. As determined on an array of cell lines, cell populations with transcript levels of 0.5 compared to HL60 were scored negative for ABCA3 protein detection by western blot or immunocytology. In the statistical evaluation of the in-vitro experiments, differences between cohorts of samples with and without experimental intervention were tested using the two-tailed Student's t-test, and differences with Po0.05 were considered significant.
Results
Expression and clinical relevance of ABCA3 in acute myeloid leukemia
Following from the identification of ABCA3 expression in leukemic progenitor cells with the SP phenotype in an in-vivo model system, 8 here we analyzed the expression of ABCA3 in a cohort of 81 pediatric and 38 adult patients at the time of first diagnosis with AML (Supplementary Table 1 ). Transcripts of the transporter were detectable in all samples, with expression levels varying over a wide range of four log scales, whereas ABCA3 transcripts were not, or only at very low levels, detectable in normal whole bone marrow samples (Figure 1c) . Interestingly, AML patients displayed remarkable differences between individuals (Figures 1a and b) . Furthermore, when an individual patient proved to be ABCA3 positive, the intercellular distribution within the blast population was significantly heterogeneous (Figure 1b) . In questioning the impact of ABCA3 on the efficacy of chemotherapy of patients with AML, we analyzed patients at first presentation of disease and who had not undergone any immunotherapy in the form of allogeneic stem cell transplantation during the observation period (n ¼ 87). Thus, we found high levels of ABCA3 significantly associated with both reduced PFS (Figure 2a ; P ¼ 0.0069) and OS of the patients (Figure 2b ; P ¼ 0.013). These differences were still significant when stem cell transplant recipients were included (n ¼ 109, Supplementary Figure 1) . The survival differences between groups of high and low levels of ABCA3 expression were also evident within the prognostic cytogenetic subgroups (Supplementary Figure 1) . Performing multivariate analysis using Cox regression, ABCA3 levels separated outcome independently of karyotype implications (Supplementary Figure 1) . Beyond AML, we discovered a significant expression of ABCA3 also in a broad spectrum of transformed hematopoietic cells. Among the hematopoietic malignancies, ABCA3 levels were highest in the aggressive B-cell lymphomas, both on the level of cell lines and clinical tissues (Figure 7) . Thus, we found significant expression of ABCA3 in the blasts of patients with AML, and high levels of expression were found to be associated with poor treatment outcome.
Induction of a multidrug resistance phenotype by ABCA3 in HEK293 and HL60 cells
Addressing the question as to whether ABCA3 expression is able to mediate drug resistance in a similar fashion to other ABC transporters, we compared the susceptibility of a stable transfectant expressing ABCA3, HEK293-ABCA3/eGFP, to the parental, ABCA3-negative reporter cell line HEK293 after exposure to a panel of cytostatic drugs. As shown in Figure 3 , ABCA3 overexpression induces a significant reduction in cytotoxicity observed following exposure to DNR, mitoxantrone, etoposide, Ara-C and vincristine (Figure 3a) . The protective effect of ABCA3 expression was not observed on exposure to the immunotoxin GO, which would not bind to CD33-negative HEK293 cells (Figure 3a) . The ABCA3-mediated protection of HEK293 cells from cytotoxic damage by soluble substances could be significantly reduced by functional knockdown of ABCA3 with a specific siRNA (Figure 3b , here shown for DNR). Beyond direct cytotoxicity, we also analyzed the effects of ABCA3 on clonogenicity in the HEK293 in-vitro model. In correlation with the viability assays, ABCA3 expression markedly increases the fraction of cells with the capacity of clonal regrowth following exposure to chemotherapy in clonogenicity tests, and does not alter the susceptibility to g-and UV-radiation (Supplementary Figure 2A) . A nonfunctional, mutated variant N568D-eGFP of ABCA3 does not induce drug resistance, and specific siRNA against ABCA3 increases the cytotoxic efficacy of DNR, etoposide and Ara-C (Supplementary Figure 2C, D) . Thus, ABCA3 function is associated with a multidrug resistance phenotype, both in the HEK293 and HL60 leukemic cell models.
Localization of ABCA3 to the late endosomal compartment
Under high-power magnification, we had already observed a cytoplasmic staining pattern in primary leukemic cells stained for ABCA3 (Figure 1b) . Correspondingly, ABCA3 is found delineating cytoplasmic organelles in the HEK293-ABCA3/eGFP variant cells (Figure 4a) . Such subcellular fluorescence colocalizes with markers for late endosomal and lysosomal membranes, that is, the LAMP1 (Figure 4a ), but not with markers of the early endosomal compartment such as EEA1 or Golgi/early endosomes (MPR46, data not shown). Furthermore, ABCA3 colocalizes clearly with fluorescent agents staining the lumen of acidic organelles, such as the vital dye Lysotracker Red (Figure 4a) . Staining with Lysotracker Red also reveals a fourfold augmentation of dye retention per cell in the cells expressing ABCA3 when compared to the wt cell line (Figure 4b ). In addition, the extended lysosomal volume in ABCA3-positive cells is associated with an increase in lysosomal membrane proteins such as LAMP1 and 2 (Figure 4c ), as well as some, but not all lysosomal matrix enzyme activity (data not shown). To further characterize the ABCA3-positive organelles, we examined the wt and transfectant HEK293, as well as primary leukemic cells under an electron microscope. In HEK293 cells, ABCA3 overexpression leads to a significant increase in the number of organelles of the late endosomal system, that is, lysosomes, multivesicular bodies and multilamellar bodies (Figures 5b and c) . Correspondingly, we also detected an excessive accumulation of lysosomes in the cytoplasm of leukemic blast cells isolated from patients with AML, yet not as many multilamellar or multivesicular bodies (data not shown). In line with the observations using confocal microscopy, we again noticed colocalization of ABCA3 and LAMP1 on the limiting membrane of the lysosome (Figure 5d ). Thus, ABCA3 is expressed in the membranes of the late endosomal system in leukemic and ABCA3-transfected cells, and increased transporter expression augments the endosomal system.
ABCA3-mediated subcellular drug sequestration
Subcellular drug sequestration with subsequent reduction of the active substance at the intracellular site of action may be viewed as contributing to multidrug resistance. 13 Exploiting the fluorescence of DNR in order to track its location in the cell using confocal microscopy, we depicted DNR fluorescence concentrated in vesicular organelles showing ABCA3/eGFP fluorescence (Figure 6a ). These experiments revealed that DNR accumulated in the ABCA3-positive vesicles in parallel to the nuclear accumulation during drug exposure. After 24 h washout, the ABCA3-positive vesicles still retained the drug, whereas the nucleus was found cleared of DNR fluorescence (Figure 6a) . Accordingly, subcellular fractionation of such cells revealed DNR in the fraction of lysosomal content with lysosomal b-hexosaminidase activity and expression of the lysosomal membrane protein LAMP1, and only to a very minor degree in the endosomal fractions with expression of the early endosomal marker MRP46 (Figure 6c) . Finally, together with the increased lysosomal retention of DNR, we observed a greater accumulation of DNR in the ABCA3-positive cells, albeit associated with a reduction in nuclear DNR levels in cells overexpressing ABCA3 (Figures 6b and 7) . Our data are consistent with the efficient sequestration of DNR in the lysosomal space, thus reducing the amount of drug reaching the nucleus.
Discussion
We report here on the expression of the genuine intracellular ABCA3 in AML, document its association with poor outcome of disease in AML, present evidence of its capacity to protect cells against the toxic effects from an array of cytotoxic drugs and propose drug sequestration into lysosomes/lysosomal-related organelles as the mechanism for its protective effects.
Since the initial description of drug resistance by the permeability glycoprotein (MDR1), drug extrusion by ABC transporters has been studied extensively. [13] [14] [15] It was in AML that MDR1 expression was first found to be associated with poor response to treatment. 16, 17 Out of a family of 48 human ABC transporters, further proteins such as MRP1, its homologues MRP2, MRP3, MRP5 and the breast cancer resistance protein (BCRP or ABCG2) were detected in leukemic blasts at variable degrees of expression, and have been linked to clinically relevant drug resistance in AML. These transporters are located in the plasma membrane, thus making reductions in total cell drug retention a conceivable explanation for the resistant phenotype. 18 Beyond total cell drug levels, however, the phenomenon of cytostatic drug sequestration in cytoplasmic vesicles has been described in several drug-resistant cell lines, and atypical intracellular activity of genuine plasma membrane transporters such as MDR1 and MRP1 has been implicated. 19, 20 It was subsequently observed that the cytoplasmic structures that retained drugs were acidic in nature, that is, lysosomes and endosomes. 20 Following this concept, weak bases such as anthracyclines accumulate in acidic compartments become membrane impermeable through protonation and are thus kept apart from the nucleus.
Our findings on the genuine intracellular transporter ABCA3 are congruent with this model and may at least in part explain some of the experimental observations cited above: a high degree of ABCA3 transporter expression leads to augmentation of the late endosomal/lysosomal storage capacity, which is acidic in nature, and improved efficacy of drug sequestration, thus protecting the nuclear or cytoplasmic drug targets from any toxic effect. We speculate that ABCA3 overexpression has an impact on the cellular detoxification of all drugs, the extrusion of which involves late endosomal/lysosomal transporters and pathways. This would explain the broad spectrum of drug resistance associated with ABCA3 overexpression.
The question still remains as to how the concept of ABCA3-mediated drug resistance via augmentation of the late endosomal system fits with previous reports on ABCA3.
ABCA3 was cloned originally from the cDNA of a human cancer cell line. 21 It is highly conserved between mammalian species, and was found expressed predominantly in the alveolar type II cells of the lung. 11, 22 In alveolar cells, ABCA3 function is essential to the formation of lamellar bodies, a lysosomal-related organelle, and indispensable for pulmonary surfactant production and/or secretion. A loss of ABCA3 function leads to fatal respiratory stress syndrome in neonates. 23 In vitro, ABCA3 is necessary, but not sufficient for the formation of mature lamellar bodies in alveolar cells, leading to the concept that, in addition to ABCA3, other surfactant proteins such as SP-B are required for the transition of lysosomes to distinct lamellar bodies. 10, 24 Besides its function in the lungs, several reports also provided first evidence of a possible role of ABCA3 in cancer cell drug resistance. In a matched pair analysis on a panel of 22 cell lines and their resistant variants on the genomic level, ABCA3 was found to be overexpressed in three resistant variants with an increase in gene copy numbers as the mechanism of ABCA3 abundance. 25 Likewise, drug-resistant variants of human T-lymphoblastic cell lines displayed an increase in ABCA3 expression levels in comparison with the parental lines, in this study due to transcriptional upregulation. 26 Furthermore, utilizing RT/PCR Steinbach et al. 27 detected ABCA3 expression in a cohort of 42 pediatric AML samples, and reported significantly higher levels of ABCA3 in 21 patients with poor treatment outcome, compared to 21 patients who benefited from chemotherapy. Finally, in addition to the data of this report, significant ABCA3 expression was identified in cells of epithelial neoplasms such as neuroblastoma and breast cancer. 7 In this context, Stahlman et al. 28 recently detected ABCA3 expression in a number of nonpulmonary tissues from both adults and children, such as the epithelia of the liver, pancreas, stomach, trachea, larynx, adrenal cortex, proximal renal tubules and the Purkinje cells in the cerebellum. We thus speculate that ABCA3 is an essential factor in the formation of late endosomes/ lysosomes in many different cell types at defined stages of differentiation, with the transition to high levels of expression and a role for the formation of specialized organelles and functions in a few tissues, such as the formation of lamellar bodies and surfactant excretion in type II pneumocytes. Associated with malignant transformation, however, transcriptional control of ABCA3 expression is lost, leading to high levels of ABCA3 expression. From a clinical perspective, our findings suggest the interference with lysosomal sequestration mechanisms as a promising avenue to be explored in order to modulate the susceptibility of leukemia cell toward cytostatic agents. We envision the interference with ABCA3 by a specific inhibitor, or the inhibition of lysosomal function by lysosomotropic substances, for example, chloroquine as such options.
In summary, the ABCA3 is expressed in the cells of AML, and mediates clinically relevant multidrug resistance by drug sequestration in late organelles of the endosomal system. We view the interference with detoxification pathways related to ABCA3 in tumor cells to be a very promising approach to improving the efficacy of cytostatic treatment.
